Journal of Isfahan Medical School

Journal of Isfahan Medical School

Comparison of Azithromycin and Erythromycin Effects in Reducing Preterm Premature Rupture of Membranes Outcomes: A Clinical Trial Study

Document Type : Original Article(s)

Authors
Mohadeseh Besharati 1
Atiyeh Javaheri 2
Noushin Hatamizadeh 2
Farimah Shamsi 3
1 Student of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2 Associate Professor, Department of Obstetrics and Gynecology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 Assistant Professor, Department Biostatistics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
10.48305/jims.v41.i730.0643
Abstract
Background: Preterm premature rupture of membranes (PPROM) is one of the important causes of perinatal mortality. This study aimed to compare the effects of azithromycin and erythromycin on pregnancy outcomes in mothers with PPROM.
Methods: In this clinical trial study, patients diagnosed with PPROM between 24 and 34 weeks were treated with two drug regimens. Group A (n = 30) received oral azithromycin one-gram single dose and Group B
(n = 30) received oral erythromycin 400 mg every 6 hr for 7 days. In addition, both groups were treated with intravenous ampicillin 2 grams every 6 hours for 48 hours and then amoxicillin 250 mg orally every 8 hours for 5 days. Primary outcomes including latency period and clinical chorioamnionitis and secondary outcomes including the type of delivery, amniotic fluid stained with meconium, postpartum endometritis, neonatal sepsis, baby's birth weight, and live birth rate were compared between the two groups.
Findings: In the current study, the latency period was significantly higher, while postpartum endometritis and laboratory-confirmed neonatal sepsis were significantly lower in the azithromycin group than in the erythromycin group. Other outcomes did not show significant differences between the two groups.
Conclusion: Azithromycin is more effective than erythromycin in the increased latency periods and decreased postpartum endometritis and neonatal sepsis in women with PPROM. Therefore, azithromycin can be a suitable alternative to erythromycin in the treatment of PPROM.
Keywords
Azithromycin
Erythromycin
PPROM
Pregnancy outcomes
Subjects
  1. Gitobu CM, Gichangi PB, Mwanda WO. The effect of Kenya’s free maternal health care policy on the utilization of health facility delivery services and maternal and neonatal mortality in public health facilities. BMC Pregnancy Childbirth 2018; 18(1): 77.
  2. Lannon SMR, Vanderhoeven JP, Eschenbach DA, Gravett MG, Waldorf KMA. Synergy and interactions among biological pathways leading to preterm premature rupture of membranes. Reprod Sci 2014; 21(10): 1215-27.
  3. Menon R, Behnia F, Polettini J, Richardson LS. Novel pathways of inflammation in human fetal membranes associated with preterm birth and preterm pre-labor rupture of the membranes. Semin Immunopathol 2020; 42(4): 431-50.
  4. Stancu SMK, Ash LK, Smeding C, Alwan MA. Predictors of caesarean delivery in preterm premature rupture of membranes. Open Access Maced J Med Sci 2019; 7(7): 1124-8.
  5. Addisu D, Melkie A, Biru S. Prevalence of preterm premature rupture of membrane and its associated factors among pregnant women admitted in Debre Tabor General Hospital, North West Ethiopia: institutional-based cross-sectional study. Obstet Gynecol Int 2020; 2020: 4034680.
  6. TC O, Enwereji J, Okoro OS, Adiri C, Ezugwu E, Agu P. The incidence and management outcome of preterm premature rupture of membranes (PPROM) in a tertiary hospital in Nigeria. Am J Clin Med Res 2014; 2(1): 14-7.
  7. Onwughara CE, Moodley D, Valashiya N, Sebitloane M. Preterm prelabour rupture of membranes (PPROM) and pregnancy outcomes in association with HIV-1 infection in KwaZulu-Natal, South Africa. BMC Pregnancy Childbirth 2020; 20(1): 204.
  8. Armstrong-Wells J, Post MD, Donnelly M, Manco-Johnson MJ, Fisher BM, Winn V. Patterns of placental pathology in preterm premature rupture of membranes. J Dev Orig Health Dis 2013; 4(3): 249-55.
  9. Nunes V, Cross J, Speich JE, Morgan DR, Strauss 3rd JF, Ramus RM. Fetal membrane imaging and the prediction of preterm birth: a systematic review, current issues, and future directions. BMC Pregnancy Childbirth 2016; 16(1): 387.
  10. Medina TM, Hill DA. Preterm premature rupture of membranes: diagnosis and management. Am Fam Physician 2006; 73(4): 659-64.
  11. Marchant JM, Petsky HL, Morris PS, Chang AB. Antibiotics for prolonged wet cough in children. Cochrane Database of Systematic Reviews. Cochrane Database Syst Rev 2018; 7(7): CD004822.
  12. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003; 330(5): 1005-14.
  13. Liang JH, Han X. Structure-activity relationships and
    mechanism of action of macrolides derived from erythromycin as antibacterial agents. Curr Top Med Chem 2013; 13(24): 3131-64.
  14. Lau A, Bradshaw CS, Lewis D, Fairley CK, Chen MY, Kong FY, et al. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. Clin Infect Dis 2015; 61(9): 1389-99.
  15. Oliver ME, Hinks TSC. Azithromycin in viral infections. Rev Med Virol 2021; 31(2): e2163.
  16. Antonucci R, Cuzzolin L, Locci C, Dessole F, Capobianco G. Use of azithromycin in pregnancy: More doubts than certainties. Clin Drug Investig 2022; 42(11): 921-35.
  17. Amsden GW, Gray CL. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother 2001; 47(1): 61-6.
  18. Salman S, Rogerson SJ, Kose K, Griffin S, Gomorai S, Baiwog F, et al. Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob Agents Chemother 2010; 54(1): 360-6.
  19. Navathe R, Schoen CN, Heidari P, Bachilova S, Ward A, Tepper J, et al. Azithromycin vs erythromycin for the management of preterm premature rupture of membranes. Am J Obstet Gynecol 2019; 221(2): 144.e1-e8.
  20. Fitzgibbon A, Clooney L, Broderick D, Eogan M, McCallion N, Drew RJ. Erythromycin compared to amoxicillin and azithromycin for antimicrobial prophylaxis for preterm premature rupture of the membranes: a retrospective study. J Obstet Gynaecol 2021; 41(4): 569-72.
  21. Seaman RD, Kopkin RH, Turrentine MA. Erythromycin versus azithromycin for treatment of preterm prelabor rupture of membranes: A systematic review and meta-analysis. Am J Obstet Gynecol 2022; 226(6): 794-801.e1.
  22. Musavi E, Hashemi Dizaji S, Chamani M, Mohammadianamiri M. Comparison of azithromycin versus erythromycin on gestation length (prolongation of latency interval) and neonatal outcomes in pregnant women with premature rupture of the membrane: A randomized clinical trial. Int J Pediat 2022; 10(11): 16934-40.
  23. Martingano D, Singh S, Mitrofanova A. Azithromycin in the treatment of preterm prelabor rupture of membranes demonstrates a lower risk of chorioamnionitis and postpartum endometritis with an equivalent latency period compared with erythromycin antibiotic regimens. Infect Dis Obstet Gynecol 2020; 2020: 2093530.
  24. Mohamed M, El-Sherbeny M, Elsayed MA, Rezk A. Azithromycine versus erythromycine in preterm premature rupture of membrans. Zagazig Univ Med J
    2015; 21(5): 1-8.
  25. Pierson RC, Gordon SS, Haas DM. A retrospective comparison of antibiotic regimens for preterm premature rupture of membranes. Obstet Gynecol 2014; 124(3): 515-9.
  26. Finneran MM, Appiagyei A, Templin M, Mertz H. Comparison of azithromycin versus erythromycin for prolongation of latency in pregnancies complicated by preterm premature rupture of membranes. Am J Perinatol 2017; 34(11): 1102-7.
  27. Abdelfattah LE, Aboshama RA, Abdelbadie AS, Abulhasan MH, Anan MA, Abdelaal II. Different azithromycin protocols for management of preterm prelabour rupture of membranes: a randomized clinical trial. BMC Pregnancy Childbirth 2022; 22(1): 869.
  28. Navathe RS, Heidari P, Ward A, Hoffman M, Berghella V, Roman A. 400: Azithromycin vs. Erythromycin for the management of preterm premature rupture of membranes. Am J Obstet Gynecol 2017; 216(1): S239-40.
  29. Mobaraki N, Ghazi A, Sadeghie Ahari S, Mohammad
    Shahi J, Pirozan P. Comparison of the prevalence of Mycoplasm hominis infection in pregnant women with and without preterm premature rupture of membranes and the relationship of this infection with preterm premature rupture of membranes [in Persian]. Iran J Obstet Gynecol Infertil 2019; 22(4): 1-10.
  30. Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Combination of tocolytic agents for inhibiting preterm labour. Cochrane Database Syst Rev 2014; (7): CD006169.
  31. Hancox JC, Hasnain M, Vieweg WVR, Crouse ELB, Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports. Ther Adv Infect Dis 2013; 1(5): 155-65.
  32. Schreiber H, Shitrit P, Man-El G, Engel O, Berkovitz A, Biron-Shental T. Macrolide antibiotics roxithromycin vs. azithromycin for preterm premature rupture of membranes: a retrospective comparison. Arch Gynecol Obstet 2019; 300(3): 569-73.
Journal of Isfahan Medical School
Volume 41, Issue 730
2nd Week, October
September and October 2023
Pages 643-651

  • Receive Date 18 April 2023
  • Accept Date 01 September 2023